Welcome to our dedicated page for Agios Pharmaceuticals SEC filings (Ticker: AGIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Agios Pharmaceuticals, Inc. filings document the regulatory record of a Delaware, Nasdaq-listed commercial-stage biopharmaceutical company focused on rare diseases and hematology. Its 8-K reports furnish operating results, product revenue updates for PYRUKYND® and AQVESME™, business highlights, investor presentations, and Regulation FD disclosures tied to mitapivat commercialization, clinical programs, and regulatory interactions.
Proxy and current-report filings cover annual-meeting proposals, director elections, board-class structure, committee assignments, stockholder voting matters, and compensatory arrangements for directors. Other disclosures address board appointments, pharmacovigilance communications involving PYRUKYND, exhibit filings, and Inline XBRL cover-page data.
AGIOS PHARMACEUTICALS director Rahul D. Ballal reported equity compensation transactions. He exercised 2,816 restricted stock units into common stock and, after these transactions, directly holds 15,230 common shares.
On the same date, he received 14,950 stock options at an exercise price of $34.16 per share, expiring on June 18, 2036, and 2,927 new restricted stock units. Footnotes state the exercised RSUs were granted on June 18, 2025 and vested on June 18, 2026, while the new RSUs and options were granted on June 18, 2026 and will vest in full on June 18, 2027.
AGIOS PHARMACEUTICALS director Jeffrey D. Capello reported equity awards and vesting activity. On June 18, 2026, 2,816 restricted stock units converted into the same number of common shares, increasing his direct holdings to 10,865 shares.
He also received new grants of 14,950 stock options with an exercise price of $34.16 per share, expiring on June 18, 2036, and 2,927 restricted stock units. According to the footnotes, options and RSUs granted on June 18, 2026 vest in full on June 18, 2027, with vested shares delivered within three business days. Earlier RSUs granted June 18, 2025 vest in full on June 18, 2026. These are compensation-related grants and exercises, not open-market purchases or sales.
AGIOS PHARMACEUTICALS, INC. director Kaye I. Foster-Cheek reported routine equity compensation and an option-related share delivery. On June 18, 2026, she exercised restricted stock units covering 2,816 shares of common stock, increasing her direct holdings to 10,284 shares. She also received a grant of 14,950 stock options with a $34.16 exercise price, expiring on June 18, 2036, and a separate award of 2,927 restricted stock units that will vest in full on June 18, 2027. In addition, 2,200 shares are held indirectly through the Foster Family Revocable Trust. These movements reflect compensation and conversions rather than open-market buying or selling.
AGIOS PHARMACEUTICALS director Jacqualyn A. Fouse reported equity compensation and a routine vesting event. On June 18, 2026, 2,816 restricted stock units vested and were converted into 2,816 shares of common stock, bringing her direct common stock holdings to 154,156 shares.
On the same date, she received new awards of 14,950 stock options with a strike price of $34.16 per share, expiring on June 18, 2036, and 2,927 new restricted stock units. These 2026 option and RSU grants are scheduled to vest in full on June 18, 2027. The filing shows only acquisitions, with no reported share sales.
AGIOS PHARMACEUTICALS director Maykin Ho reported compensation-related equity transactions. She exercised restricted stock units into 2,816 shares of common stock, bringing her direct holdings to 19,848 shares. She also received 14,950 stock options and 2,927 new restricted stock units, which vest in future years.
AGIOS PHARMACEUTICALS, INC. director Catherine Owen Adams reported equity compensation activity involving stock options, restricted stock units (RSUs), and common shares. She exercised RSUs to receive 2,816 shares of common stock, bringing her direct common stock holdings to 10,865 shares.
On the same date she was granted 14,950 stock options with a $34.16 exercise price, vesting fully on June 18, 2027, and 2,927 RSUs that also vest in full on June 18, 2027. Footnotes state earlier RSUs granted June 18, 2025 vested June 18, 2026, with shares delivered within three business days.
AGIOS PHARMACEUTICALS, INC. director David Scadden increased his equity-based holdings through option and RSU activity. On June 18, 2026, he acquired 2,816 shares of common stock via the exercise of previously granted restricted stock units, bringing his direct common stock ownership to 20,419 shares.
He also received new equity awards: 14,950 stock options with a $34.16 exercise price, vesting in full on June 18, 2027, and 2,927 new restricted stock units that also vest in full on June 18, 2027. Earlier RSUs granted on June 18, 2025 will vest in full on June 18, 2026, with shares delivered within three business days after vesting.
AGIOS PHARMACEUTICALS director Cynthia Smith reported equity compensation activity and an option exercise. On June 18, 2026, she exercised restricted stock units covering 2,816 shares of common stock, bringing her direct common stock holdings to 15,230 shares after the transaction.
She also received 14,950 stock options with an exercise price of $34.16 per share that vest in full on June 18, 2027, and 2,927 new restricted stock units that also vest on June 18, 2027. Earlier restricted stock units granted on June 18, 2025 vested in full on June 18, 2026, and the vested shares will be delivered within three business days after vesting.
AGIOS PHARMACEUTICALS, INC. reported that Chief Strategy and Operations officer Krishnan Viswanadhan acquired equity-based compensation on June 18, 2026. He received 3,000 restricted stock units, each representing a contingent right to one share of common stock, and a further 3,000 performance share units tied to clinical and research milestones. The performance share units were originally granted on March 5, 2025, and the compensation & people committee determined that the performance criteria for a specified research milestone were met as of June 18, 2026. Shares related to that milestone are scheduled to vest on December 31, 2027, subject to his continued service.
AGIOS PHARMACEUTICALS, INC. Chief Executive Officer Brian Goff reported equity compensation activity involving 39,000 shares. He received a grant of 39,000 restricted stock units, each representing a contingent right to receive one share of common stock. In addition, 39,000 performance share units tied to clinical and research milestones were exercised into underlying common stock. The performance criteria for a specified research milestone were determined to be met as of June 18, 2026, and the related shares are scheduled to vest on December 31, 2027, subject to his continued service.